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Metastasis is the cause of more than 90% of all cancer deaths. Despite this fact, most anticancer therapeutics
currently in clinical use have limited efficacy in treating established metastases. Here, we identify the endoplasmic
reticulum chaperone protein, glucose-regulated protein 78 (GRP78), as a metastatic dependency in several highly
metastatic cancer cell models. We find that GRP78 is consistently upregulated when highly metastatic cancer cells
colonize the lungmicroenvironment and thatmitigation of GRP78 upregulation via short hairpin RNA or treatmentwith
the small molecule IT-139, which is currently under clinical investigation for the treatment of primary tumors, inhibits
metastatic growth in the lung microenvironment. Inhibition of GRP78 upregulation and an associated reduction in
metastatic potential have been shown in four highlymetastatic cell linemodels: three human osteosarcomas and one
murinemammary adenocarcinoma. Lastly, we show that downmodulation of GRP78 in highly metastatic cancer cells
significantly increases median survival times in our in vivo animal model of experimental metastasis. Collectively, our
data indicate that GRP78 is an attractive target for the development of antimetastatic therapies.
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Significant strides have been made toward the improvement of overall
survival in cancer patients with localized disease. Treatment of
patients with metastatic disease, or at risk for metastatic progression,
remains to be a challenge as metastases account for more than 90% of
cancer-related deaths [1]. To develop effective antimetastatic
therapeutics that address this unmet clinical need, further under-
standing of molecular drivers that allow a cancer cell to successfully
complete all steps of the metastatic cascade is needed [2,3]. The lung
is a common site of metastasis for many types of solid tumors
including breast, prostate, melanoma, and pediatric osteosarcoma
(OS). Pediatric OS is of particular interest because it is a solid tumor
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disease model that permits researchers to identify targets that
influence lung metastatic progression [4]. Our laboratory has several
OS models that have proved useful for gaining insight into some of
the molecular pathways contributing to metastatic colonization of the
lung by OS [4–6].
During the process of lung metastasis progression, the majority of
tumor cells that disseminate to the lung fail to establish clinically
detectable metastases [7]. Indeed, experimental data from our
laboratory and other groups suggest that the majority of cancer cells
that arrive in the lung microvasculature undergo apoptosis and that a
common feature of highly metastatic cells is their unique ability to
resist apoptosis in the lung [4,8]. In contrast, poorly metastatic cells
show higher rates of apoptosis in this microenvironmental setting.
These data suggest that metastatic cancer cells with a high metastatic
potential are better adapted to meet the challenges of growing in the
hostile microenvironment such as the lung. Indeed, such challenges
may include 1) differences in oxygen tension, 2) reactive oxygen and
nitrogen species, and 3) differences in nutritional sources [4,9]. To
successfully establish overt metastasic tumors in the lung, metastatic
cancer cells must quickly adapt to fluctuations in microenvironment
and maintain cellular homeostasis as they arrive and grow within this
hostile microenvironment [10,11]. To understand how metastatic
cancer cells adapt to the lung microenvironment, we turn our
attention to the endoplasmic reticulum (ER) because it is known to
be a central organelle in both sensing a variety of cellular stresses and
initiating homeostatic responses that attempt to ameliorate the stress
or commit the cell to apoptosis [12].
The ER is an extensive tubular network that extends throughout
the cell and is the site where one third of all cellular proteins are
produced and processed [12]. Protein folding and chaperone activity
within the ER are dependent on multiple factors including 1) ATP
supply, 2) redox state, 3) Ca2+ levels, and 4) nutrients supply, all of
which make ER function exquisitely sensitive to external environ-
mental conditions [13,14]. When adverse environmental conditions
interfere with ER function, misfolded/unfolded proteins accumulate
(a condition known as ER stress). ER membrane “stress sensors”
(IRE1, PERK, and ATF6) detect ER stress and initiate a
transcriptional program that increases ER function by upregulating
foldases, chaperones, and co-chaperones. Glucose-regulated protein
78 (GRP78) is a major ER molecular chaperone that is upregulated
during this adaptive response, and participates in protein folding and
prevents protein aggregation [15]. GRP78 is found to be upregulated
in many types of cancers [16]. GRP78 upregulation has been
associated with chemoresistance [17,18], and interestingly, the
protein itself has been found to have antiapoptotic activity in breast
cancer cells [19]. Considering the microenvironmental stresses
metastatic cancer cell encounters in the lung and how the ER plays
a major role in the induction of cellular adaption to such stresses, it is
reasonable to hypothesize that the adaptive ER-stress response,
particularly the upregulation of GRP78, is required for an aggressive
highly metastatic phenotype.
The following report provides the first functional link between the
induction of an adaptive ER-stress response (GRP78 upregulation)
and an aggressive metastatic phenotype. More specifically, highly
metastatic cancer cells differentially upregulate GRP78 compared
with poorly metastatic cancer cell when growing in the lung or when
challenged with pharmacological drugs that induce ER stress in vitro.
Moreover, GRP78 upregulation is linked to metastatic aggressivenessbecause inhibition of GRP78 results in lower lung tumor burden and
higher median survival times in our animal models. Collectively, these
data suggest that GRP78 upregulation in metastatic cancer cells is a
critical driver of their metastatic success and that the capacity of
metastatic cancer cells to elicit this response directly correlates with
metastatic potential. Our observations add an important translational
rationale to the clinical development of therapeutic agents (i.e.,
IT-139) that target these ER-stress adaptation pathways. These data
and treatment rationale are well aligned with the recent recognition of
the importance for drug development approaches that target
metastatic progression in cancer patients.Materials and Methods
Cell Culture and Materials
Human OS cell lines MG63, MNNG, HOS, and 143B and the
murine mammary carcinoma cell lines 4T1 and 67NR were all
obtained from ATCC. MNNG, 143B, and 4T1 cells are
characterized to have a highly metastatic phenotype in vivo [20,21].
The MG63.3 cell line is a highly metastatic clonal variant of the
human OS cell line established from MG63.2 cells, which were in
turn established from the MG63 cell line [21]. The MG63, HOS,
and 67NR cell lines were previously characterized to have a poorly
metastatic phenotype in vivo [20]. To visualize cells by fluorescence
microscopy, all cells were transduced with enhanced green fluorescent
protein (eGFP) where the cytomegalovirus promoter (for human
cells) or pol II promoter (for murine cells) was used to drive eGFP
expression. The MG63, MG63.3, HOS, MNNG, and 143B cell
lines were authenticated by short tandem repeat DNA profiling at the
University of Colorado DNA Sequencing and Analysis Core in
September 2014. 4T1 and 67NR cells that were originally obtained
from ATCC have not been authenticated further. All cell lines are
routinely tested for mycoplasma contamination using the Lonza
MycoAlert Plus. The small molecule inhibitor of GRP78 expression
IT-139 was kindly provided by Intezyne. All cell lines were
maintained in Dulbecco's modified essential medium (Invitrogen)
containing 10% fetal bovine serum, 5% penicillin/streptomycin (100
U/ml) at 37°C, and 5% CO2.
Transcriptome Profiling of Highly Metastatic Cells and Poorly
Metastatic Cells Grown in 2D Cell Culture and in the Lung
To survey and compare the expression of ER-stress responsive
genes in highly metastatic cells and poorly metastatic tumor cells
growing in 2D cell culture conditions or in the lung, tumor cell RNA
was isolated from cells growing in cell culture plates, as well as from
early and later stages of metastasis in the pulmonary metastasis assay
(PuMA) model (1 day and 14 days postinjection), as described by
Morrow and colleagues [22]. Briefly, RNA was isolated from
MG63.3 and MG63 cells growing in cell culture plates by the
standard TRIzol method. Because the contrasting growth kinetics of
the MG63.3/MG63 pair were previously well characterized in the
PuMA model, we decided to obtain RNA material from MG63.3 or
MG63 growing in the lung at early and late time points in the
progression of metastatic growth. PuMA lung sections containing
eGFP-expressing tumor cells were physically minced with fine scissors
and digested with 1 mg/ml of collagenase (Roche) in Hank's balanced
salt solution at 37°C for 30 minutes. The digestion was stopped by
adding 10 mM EDTA. The lung digest was homogenized by passing
through an 18G needle attached to a 10-ml syringe and passed
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500 ×g for 5 minutes at 4°C. The supernatant was aspirated, and cell
pellet was resuspended in 5 ml of ammonium-chloride-potassium
lysing buffer for 3 minutes at room temperature to lyse red blood
cells. Red blood cell lysis was stopped by adding 10 ml of Hank's
balanced salt solution, and cells were centrifuged for 5 minutes at 4°C.
The supernatant was discarded, and cells were resuspended in 3 ml of
PBS with 0.5 mM EDTA and placed on ice. eGFP-positive MG63.3
and MG63 cells were isolated by fluorescent activated cell sorting.
Sorted eGFP human OS cells were centrifuged, the cell pellet was
lysed in 1 ml of TRIzol reagent (Life Technologies), and RNA was
isolated using standard procedures using chloroform. RNA samples
were further processed using the RNAeasy Micro Kit (Qiagen). RNA
quality was assessed using a 2200 Tapestation Instrument (Agilent).
PolyA+ RNA was prepared by using the Illumina Truseq RNA
Sample Preparation kit as per manufacturer's instructions. Samples
were sequenced using the Illumina HiSeq 2500 platform.
To find ER-stress responsive genes that were preferentially
upregulated only in highly metastatic versus poorly metastatic cancer
cells in the lung, RNA sequencing data were parsed using a list of
genes known to have ER-stress elements in their promoter regions
[23]. This approach was used to identify specific parts of ER-stress
signaling pathway that may be mechanistically linked to a role for ER
stress response in metastasis. From this initial data set, the expression
profiles of a smaller subset of genes were chosen based on their
differential upregulation in highly metastatic cells versus poorly
metastatic cells in the lung microenvironment. The expression
profiles of these differentially upregulated genes were represented in a
smaller heat map.
Fluorescence Immunostaining and Confocal Imaging
For paraffin tissue sections, sections were dewaxed with xylene and
rehydrated with an alcohol series. Antigen retrieval was performed by
heating the slides at 95°C for 25 minutes in a working solution of
Target Retrieval Solution (DAKO). The slides were permeabilized
with phosphate-buffered saline with 0.01% Triton for 10 minutes.
Slides were blocked with 4% bovine serum albumen in
phosphate-buffered saline with 0.01% Triton for 10 minutes. To
detect eGFP-expressing human tumor cells in tissue sections, primary
goat antibodies (against eGFP) directly conjugated to fluorescein
isothiocyanate (Abcam) were used. To detect GRP78, polyclonal
rabbit anti-GRP78 antibodies (1:100, Abcam) were used. Goat
anti-rabbit secondary antibodies conjugated to Alexa 594 were used
to localize rabbit anti-GRP78 in tissue sections. Nuclei were
counterstained blue with 4′,6-diamidino-2-phenylindole (DAPI,
1 mg/ml; Sigma) for 5 minutes. Tissue sections stained only with
secondary antibodies served as omission controls to assess the level of
background fluorescence. Tissue sections were imaged using a Zeiss
710 laser scanning confocal microscope equipped with argon, DPSS
561, and Diode 405 lasers, where images were acquired using either a
low-power (20×) objective lens or 63× oil immersion objective lens.
Stereological Analysis of GRP78 Expression in Metastatic OS
Cells in Culture and in the Lung In Situ
GRP78 expression in metastatic cancer cells both in 2D cell culture
and in lung tissue sections was quantified using a dimensionless
stereological parameter called area fraction (AA). Described by
Underwood [24], AA is assessed on a per-cell basis and is calculated
by assessing the GRP78 (Alexa 594 red fluorescence) staining areadivided by the area of the cell (fluorescein isothiocyanate, green
fluorescence). The average area fraction of GRP78 per cell was
calculated and compared between highly metastatic cells and poorly
metastatic tumor cells growing in 2D culture in vitro and in paraffin
tissue sections of PuMA lung slices taken at 0 and 14 days
postinjection; 20 to 80 tumor cells were counted per condition.
Western Blotting
The protein concentration for cell lysates were determined by the
bicinchoninic assay (ThermoFisher), as per manufacturer's instruc-
tions. Fifteen or twenty micrograms of protein was loaded in 4% to
20%mini-gel (Invitrogen) and electrophoresed for 150 minutes at 120
V and 40 mA. After electrophoresis, gels were placed in iBlot Gel
Transfer Device (Invitrogen), and proteins were transferred to a
nitrocellulose membrane. Prior to the addition of primary antibodies,
membranes were blocked in TRIS-buffered saline with 0.1%
Tween-20 and 5% milk powder for 1 hour. Antibodies against rabbit
anti-GRP78 (1:1000, Abcam) and mouse anti-β-actin (Sigma-Aldrich)
were incubated overnight at 4°C. Membranes were washed with
TRIS-buffered saline with 0.1% Tween-20 and incubated with either
goat anti-rabbit or goat-anti-mouse IgG conjugated to horseradish
peroxidase (Sigma-Aldrich). Protein bands were visualized on film
using the Supersignal West Pico Chemiluminescent Substrate Kit
(ThermoFisher) per manufacturer's instructions.
Image Cytometry of GRP78 Expression between Highly
Metastatic Cells and Poorly Metastatic Tumor Cells under
ER Stress Conditions In Vitro
For a high-throughput quantitative analysis of how populations of
highly metastatic cells and poorly metastatic tumor cells modulate
GRP78 expression in response to ER stress, immunofluorescence
staining and single-cell image cytometry were used to quantify
GRP78 expression in highly metastatic cells and poorly metastatic
cells following exposure to tunicamycin. Briefly, 4 × 105 highly
metastatic cells and poorly metastatic cells were treated with vehicle,
50 nM tunicamycin, or 100 nM tunicamycin for 24 hours. The next
day, vehicle- and tunicamycin-treated cells were trypsinized, washed
with PBS, and fixed in cell suspension with 4% paraformaldehyde in
PBS for 12 minutes. Fixed cells were then suspended in solution of
polyclonal rabbit anti-GRP78 antibodies (1:100) in blocking buffer
and incubated overnight at 4°C. For secondary detection, goat
anti-rabbit secondary antibodies conjugated to phycoerythrin were
used. Stained cells were analyzed using a Cellometer Vision CBA
Image Cytometry System equipped with fluorescence. Image analysis
of micrographs of fluorescent stained cells was automated by using
FCS 4 Express Flow Plus Image software (DeNOVO). The number
of cells counted typically ranged from 800 to 2000 for each condition,
and the experiment was repeated twice.
GRP78 Knockdown with Lentiviral TET-ON Inducible Short
Hairpin RNA (shRNA) or IT-139 Treatment
The TET-ON (doxycycline) inducible vector used in this study is
based on the previously published shRNAmir, “miR-E,” pRRL
backbone [25]. The lentiviral version of the vector, LT3REVIR (a
kind gift from Dr. Zuber), which couples the induction of shRNA
with the expression of red fluorescent protein (dsRED), was modified
by replacing the constitutively active fluorescent reporter venus gene
with a pac (puromycin resistance) gene which enables eukaryotic
selection. Two different shRNAs against GRP78 were selected from
the transOMIC technologies shERWOOD-UltramiR shRNA
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on contract by transOMIC Technologies. The following two shRNA
antisense sequences, which target the coding region of GRP78
mRNA, were evaluated: shGRP78_1 (TATATCAACTTGAATG
TATGGT) and shGRP78_2 (TTAGCTTTGAAGTCTT
CAATGT). Ready-made lentiviral particles containing the modified
lentiviral expression vector were prepared by standard methods using
HEK cells and packaging plasmids (transOMIC Technologies). For
transduction, MG63.3 or MNNG (2 × 105 cells/well) cells were
seeded in a 6-well plate 1 day before transfection. The cells were
transfected with lentiviral particles with a multiplicity of infection = 5.
A nontargeting shRNA was used for the control. Transduced cells
were placed under selection with 2 μg/ml of puromycin for 3 days, at
which time untransduced cells were no longer surviving. After a week
of selection, over a hundred colonies of puromycin-resistant cells
formed which were subsequently pooled into one population. GRP78
protein expression in MG63.3 cells and MNNG cells is low at
baseline but is upregulated when cells are exposed to a pharmaco-
logical ER stressor (i.e., tunicamycin). Therefore, we assessed the
efficiency of knockdown in MG63.3 and MNNG cells that were
treated with tunicamycin (50 nM) for 24 hours in the presence
(doxycycline, 5-μg/ml treatment for 96 hours) or absence of
doxycycline. For subsequent tail-vein injection experiments that
assessed the metastatic potential of MG63.3 cells and MNNG cells
(where shRNA and dsRED were induced by doxycycline treatment),
cell populations were enriched for cells double-positive for eGRP and
dsRED by using a fluorescence-activated cell sorting machine, MoFlo
Astrios (Beckman Coulter), equipped with 488-nm and 561-nm
lasers to sort GFP and RFP cells, respectively.
To pharmacologically downmodulate GRP78, cancer cells were
treated with the small molecule drug IT-139 (formally NKP-1339,
kindly provided by Intezyne) which has been characterized to inhibit
GRP78 expression [26]. Inhibition of GRP78 induction (via 50-nM
tunicamycin treatment) was tested at 10, 50, 100, and 200 μM
IT-139 for 24 hours. These conditions were previously found to have
little effect on cell proliferation. Cell lysates were collected (as
previously described), and knockdown of GRP78 levels was assessed
by Western immunoblotting.
Pulmonary Metastasis Assay
To directly visualize metastatic cancer cell growth in the lung and
to assess the effects of GRP78 downmodulation on metastatic growth
over time, we used an ex vivo lung explant model called the PuMA as
described by Mendoza and colleagues [27]. Briefly, eGFP-expressing
cancer cells (3 × 105 cells for MG63.3, 2.5 × 105 cells for MNNG,
3 × 105 cells for 4T1 cells) were seeded in the lung of severe immune
compromised mice (SCID, Charles River) via tail vein injection. The
mouse was euthanized, and the lung was insufflated with 37°C 50:50
liquid mixture of media and 1.2% low-melting point agarose (Lonza)
by gravity perfusion. The agarose-filled lungs were allowed to solidify
in ice-cold PBS for 20 minutes. After the lungs solidified, fine scissors
and forceps were used to cut small lung slices (2 mm × 4 mm) which
were used for longitudinal imaging using a lower-power objective
(50× magnification) microscope. Metastatic growth for each cell line/
condition was longitudinally monitored over 14 days. For doxycy-
cline treatment or IT-139 treatment for 14 days, media and drug were
replenished every second day. For each lung slice, the stereological
parameter area fraction (AA) was calculated (see Stereological Analysis
of GRP78 Expression in Metastatic OS cells in Culture and in the LungIn Situ section for details). For drug studies and genetic knockdown
studies, 4 to 10 lung slices from 1 mouse were used per condition.
PuMA experiments were repeated three times. When lung slices were
to be imaged, lung slices were placed in a small culture dish with a
glass coverslip bottom using aseptic technique and then imaged on a
Leica DM IRB Widefield Fluorescence Microscope equipped with a
filter set appropriate for imaging eGFP.
In Vivo Experimental Metastasis Studies
All in vivo animal studies using SCID mice were performed with
the approval of the Animal Care and Use Committee of the National
Cancer Institute. For experimental metastasis survival studies, 5
groups of mice (n = 10) were studied: group 1 consisted of mice
injected with 3 × 105 human MG63.3 shGRP78_1 cells without
pretreatment of doxycycline, and mice were kept on a normal diet;
group 2 consisted of mice injected with 3 × 105 human MG63.3
shGRP78_1 cells with pretreatment of doxycycline (for 5 days), and
mice were kept on a chow with doxycycline (2 g/kg); group 3
consisted of mice injected with 3 × 105 human MG63.3 cells
shGRP78_2 cells without pretreatment of doxycycline, and mice
were kept on a normal diet; group 4 consisted of mice injected with
3 × 105 human MG63.3 shGRP78_2 cells with pretreatment of
doxycycline, and mice were kept on a doxycycline-chow diet; group 5
consisted of mice injected with 3 × 105 human MG63.3 cells with a
nontargeting control shRNA with pretreatment of doxycycline (for 5
days), and mice were kept on a doxycycline-chow diet. End point for
individual mice was reached when mice showed signs of labored
breathing from lung metastases or if there was no metastasis-related
death at 60 days. Necropsy at end point allowed the identification and
validation of pulmonary metastases in all mice. Whole lungs with the
metastases were imaged under fluorescence using a Leica MZ FLIII
Stereo-Fluorescence Dissecting Microscope equipped with a fluores-
cence light source.
Assessment of GRP78 Expression in Human OS
Immunohistochemical staining for GRP78 (Abcam) was per-
formed on a patient-derived tissue microarray (TMA) described by
Osborne and colleagues [28]. Paraffin TMA slides were processed as
previously described (see Fluorescence Immunostaining and Confocal
Imaging section). TMA slides were stained with primary antibodies
against GRP78 (Abcam) and the EnVision + System Kit (Dako) as
per manufacturer's instructions. A TMA slide stained without primary
anti-GRP78 antibodies served as an omission control to assess the level
of background staining. TMA slides were digitally scanned with a digital
whole-slide scanner (Aperio ScanScope XT; Aperio Technologies) using
a 20× objective and annotated and reviewed in Aperio ImageScope.
Quantification of GRP78 labeling was conducted on each tissue core
using the CytoNuclear Tool (Indica Laboratories) computer image
analysis algorithm. Custom settings for the CytoNuclear Tool
algorithm were determined by a pathologist prior to analysis. GRP78
expression was recorded as both a percentage of positively labeled cells
per core and the percentage of cores expressing GRP78.
Statistical Analysis
Statistical analysis data were performed using Graph Prism Statistical
Software P. For data with a normal distribution, the means were
analyzed by either unpaired t test or one-way analysis of variance to
compare multiple groups. For post hoc analysis, Tukey's multiple
comparisons test was used to assess which means were significantly
Figure 1. Differential upregulation of the ER chaperone protein GRP78 in highly metastatic MG63.3 cells versus poorly metastatic MG63
cells in the lung microenvironment. (A) Relative transcript levels of genes with ER-stress elements in their promoters in MG63.3 and MG63
cells isolated from2D in vitro cell culture conditionsor fromgrowing in thePuMAmodel at days1 and14 (larger heatmap). A smaller subset of
genes (oneofwhich isGRP78) was differentially upregulated inMG63.3 versusMG63only in the lung.NormalizedGRP78 transcript levels are
represented in the bar graph. (B) Representative confocal images of GRP78 immunofluorescence staining within OS cells in lung tissue
sections (PuMAmodel) at days 0 and 14 are shown. Triple-color immunofluorescence stainingwas used to show the location of OS cells
(green) and GRP78 (red); nuclei were counterstained with DAPI (blue). Dashed white lines delineate where GFP-expressing OS cells are
located, and the corresponding GRP78 expression in these OS cells is shown below. Scale bar = 10 μm. GRP78 staining in MG63.3 and
MG63 cells was quantified and compared for days 0 and 14, as shown in the box andwhisker plot (5%-95%percentile). Mann-WhitneyU
test, P b .001. (C) Western blot showing in vitro differential upregulation of GRP78 in MG63.3 versusMG63 cells upon 24-hour treatment
with tunicamycin (Tn). Densitometry measurements of the Western blots for MG63.3 andMG63 cells are also shown: gray bars denote
GRP78 levels; black bars show β-actin as a loading control. A time-courseWestern blot experiment showing increasing exposure times
of tunicamycin at 100 nM from 0 to 24 hours is shown. Densitometry measurements of the time-course Western blots for MG63.3 and
MG63 cells are also shown: gray bars denote GRP78 levels; black bars show β-actin as a loading control (D) Image cytometry-based
immunofluorescence quantification of GRP78 expression in MG63.3 and MG63 cells treated with tunicamycin for 24 hours. Representative
micrographs are shown. Scale bar = 40 μm. Quantification of the fold-change in the fluorescence (normalized to vehicle) is shown in the bar
graph. Mean and standard error of the mean are shown. The number of cells analyzed per group ranged from 1791 to 4090 cells.
Kruskal-Wallis test, P b .0001; Dunn's multiple comparisons test, P b .05.
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compared by either Mann-Whitney U test or Kruskal-Wallis one-way
analysis of variance. For post hoc analysis of medians, Dunn's multiple
comparisons test was used. For experimental metastasis survival studies,data were analyzed using log-rank test. P values less than .05 were
regarded as statistically significant. Mice that did not have any tumor
burden in the lung at the defined end point of 60 days were censored
from the survival data analysis.
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Subset of ER-Stress Responsive Genes Is Upregulated in Highly
Metastatic Cancer Cells in Lung
To ascertain whether the ER-stress adaptive response is induced
in metastatic cancer cells when growing in lung tissue of our PuMA
(see Materials and Methods), eGFP-expressing metastatic cancer cells
were isolated from homogenized lung tissue by FACS, and RNA was
extracted for RNA sequencing. We examined changes in expression of
genes with ER-stress response elements in their promoter region [23]
(larger heat map, Figure 1A). We further identified a smaller subset of
ER-stress responsive genes that were upregulated in highly metastatic
cancer cells versus poorly metastatic cancer cells when in the lung
microenvironment (smaller heat map, Figure 1A). Of these
upregulated genes, GRP78 (also known as heat shock protein A5)
was observed to be consistently upregulated in three highly metastatic
OS cell lines when growing in the lung microenvironment: MG63.3
cells (smaller heat map, Figure 1A), MNNG cells (smaller heat map,
Supplementary Figure 2A), and 143B cells (smaller heat map,
Supplementary Figure 3A). Normalized GRP78 transcript levels
between MG63.3 and MG63 in vitro and when growing in the lung
microenvironment at days 1 and 14 in the PuMA model are shown in
the bar graph in Figure 1A. These data show that the upregulation of a
subset of ER-stress associated genes (especially GRP78) is a common
feature of highly metastatic cancer cells.
Confocal Imaging and Validation of GRP78 Upregulation in
Highly Metastatic Cells Growing in the Lung
To validate the GRP78 transcript data at the protein level, in situ
GRP78 expression in metastatic cancer cells was assessed via
immunofluorescence staining and confocal microscopy (Figure 1B).
Image analysis reveals that highly metastatic MG63.3 cells have a
significantly larger area of GRP78 staining per cell (~42%) compared
with poorly metastatic MG63 cells (~22%) during the initial stages of
colonization in the PuMA model (day 0). Elevated levels of GRP78 in
MG63.3 cells versus MG63 cells persist to day 14 in the PuMA
model (Figure 1B). In contrast, when MG63.3 cells and MG63 cells
are grown in 2D, in vitro cell culture conditions, the average percent
staining area of GRP78 per cell is similar between the two cell lines
(Supplementary Figure 1, A and B). The specificity of GRP78
fluorescent staining was validated by showing spatial overlap with
calnexin, another marker of the ER [29]. GRP78 staining was shown
to overlap with calnexin in cells grown in vitro (Supplementary Figure
2A) and in situ PuMA lung sections (Supplementary Figure 2B).
Collectively, these results show that GRP78 staining area per
tumor cell is greater in highly metastatic cells compared with
poorly metastatic cancer cells only when growing in the lung
microenvironment.
Highly Metastatic Cancer Cells Have A Higher Fold-Change of
GRP78 Compared with Poorly Metastatic Cancer Cells under
ER Stress Conditions In Vitro
When treated with increasing concentrations of tunicamycin
for 24 hours, highly metastatic cells showed elevated GRP78
expression relative to poorly metastatic cells (dose-response upper
blots in Figure 1C). A time-course study looking at GRP78
expression at increasing exposure times in response to 100-nM
tunicamycin treatment also shows a higher accumulation of GRP78
in MG63.3 cells versus MG63 cells (time-course lower blots in Figure
1C). The differential expression of GRP78 in response to increasingconcentrations of tunicamycin was also observed by Western blotting
in two other human, highly metastatic OS cell lines: MNNG cells
(Supplementary Figure 3B) and 143B cells (Supplementary Figure
4B). High-throughput immunofluorescence-based quantification of
GRP78 expression at the single cell level (Figure 1D) demonstrates
that highly metastatic MG63.3, when normalized to vehicle
treatment, exhibited a significantly higher fold change in GRP78
expression compared with poorly metastatic MG63 cells. These data
show that highly metastatic cancer cells have a greater capacity to
respond to ER stress compared with poorly metastatic cancer cells.
Downmodulation of GRP78 in Highly Metastatic Cancer Cells
Inhibits Their Ability to Colonize Lung Tissue
A schematic of the doxycycline-inducible shRNA lentiviral
vector used to downmodulate GRP78 is shown in Figure 2A. Two
different shRNAs predicted to inhibit GRP78 expression, and a
non-targeting control, were used to address the concern of off-target
effects. The GRP78 levels following shRNA knockdown is shown by
Western blotting and densitometry (Figure 2, B and C). At baseline,
GRP78 expression is low in untreated and doxycycline-treated
MG63.3 cells. Only when GRP78 upregulation was induced by
tunicamycin treatment did we see a reduction in GRP78 protein
levels in doxycycline-treated MG63.3 cells. Because GRP78 is
post t rans lat ional ly modif ied by phosphorylat ion and
ADP-ribosylation, Western bands can be seen as doublets or triplets
[30]. Downmodulation of GRP78 showed nominal effects on cell
proliferation with shGRP78_2 and the nontargeting control shRNA
having a modest effect on cell growth (Figure 2C), indicating that
elevated expression of GRP78 is not necessary for cell survival in the
absence of stress. In the context of lung microenvironment of the
PuMA model, however, both shGRP78_1 and shGRP78_2 (when
induced with doxycycline) significantly inhibited the ability of
MG63.3 cells to colonize lung tissue (Figure 2, B and C). In contrast,
the nontargeting shRNA controls (Figure 2D) did not inhibit the
upregulation of GRP78 after tunicamycin treatment and did not
prevent outgrowth of metastatic cancer cells in the lung. Down-
modulation of GRP78 protein levels inhibiting metastatic outgrowth
in the PuMA model was recapitulated using the small molecule drug
IT-139 (Figure 2E). Treatment of MG63.3 cells with increasing
concentrations of IT-139 showed a corresponding decrease in GRP78
protein levels. Treatment of MG63.3 cells growing in lung tissue in
the PuMA model inhibited their outgrowth. We confirmed that
inhibition of GRP78 expression by shRNA or IT-139 treatment
significantly inhibited metastatic outgrowth in two other highly
metastatic human OS cell line models: MNNG, which was derived
separately from the HOS cell line (Supplementary Figure 3, C–E),
and the highly metastatic 143B cells that were also derived from HOS
cells (Supplementary Figure 4C). Collectively, the results indicate that
GRP78 upregulation is required for successful colonization of the
lung by highly metastatic human OS cells.
Downmodulation of GRP78 via shRNA Knockdown in Highly
Metastatic OS Cells Extends Median Survival Times In Vivo
A schematic of the in vivo experimental metastasis survival study
where we ascertained the effects of GRP78 knockdown using two
different shRNAs against GRP78 and a nontargeting scramble
control RNA on median animal survival is outlined in Figure 3A.
We found that mice that harbored tumors containing
doxycycline-induced shGRP78_1 or shGRP78_2 had a longer
Figure 2. Downmodulation of GRP78 via genetic knockdown or pharmacologic inhibition diminishes the metastatic potential of MG63.3
cells. A schematic diagram (A) of the doxycycline-inducible shRNA construct used in these studies. (B and C) Downmodulation of GRP78
was accomplished via two different shRNA sequences (designated shGRP78_1 and shGRP78_2, respectively) which target the coding
region of the mRNA. GRP78 protein knockdown was characterized by Western blotting; corresponding densitometry measurements are
shown, where gray bars denote GRP78 protein levels and black bars denote β-actin protein levels. Induction of shRNA via doxycycline
treatment decreased the amount of GRP78 induced by tunicamycin treatment. The effects of GRP78 downmodulation on cell
proliferation were modest but inhibited metastatic outgrowth in the PuMA model. Representative fluorescence micrographs of PuMA
lung slices with or without doxycycline treatment are shown for days 0 and 14. Quantification of lung tumor burden at day 14 is shown in
the box and whisker plot (5%-95% percentile). Unpaired t test for shGRP78_1, P b .0001, n= 10; unpaired t test for shGRP78_2, P b .0001,
n= 10. (D) A nontargeting control shRNA showed little effect on GRP78 expression, had a modest effect on in vitro cell proliferation, but
had no significant effect on lung colonization in the PuMA model. Mann-Whitney U test, box and whisker plot (5%-95% percentile), P N
.05, n = 10. (E) Downmodulation of GRP78 via IT-139 treatment. Increasing doses of IT-139 resulted in a dose-dependent knockdown of
GRP78. IT-139 treatment at 100 μM did not affect in vitro cell proliferation but inhibited metastatic outgrowth in the PuMA model, as
shown by the fluorescence micrographs. Scale bar = 1 mm. Quantification of lung tumor burden at day 14 between vehicle- and IT-139–
treated PuMA lung slices is shown in box and whisker plot (5%-95% percentile). Mann-Whitney U test, P b .01, n = 6.
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group or the induced nontargeting shRNA control group (Figure 3, B
and C). Representative ex vivo fluorescence whole-mount images
which depict the disease burden in the lungs from each group are
shown in Figure 3D. This provides evidence that targeting the ability
of a metastatic to deal with the stress of a new environment, rather
than the typical proliferation, is an attractive therapeutic strategy.GRP78 Is Expressed in Human OS Lung Metastases
We next asked whether GRP78 was expressed in human lung
metastasis tissue. A human OS patient biopsy tissue microarray was
stained for GRP78, as shown in Figure 4A. Of the 14 tissue cores, 8
cores had 80% to 100% of tumor cells staining positive for GRP78, 4
cores had 60% to 80% of tumor cells staining positive for GRP78,
and 2 cores had 40% to 60% of tumor cells (Figure 4B). Human
Figure 3. Downmodulation of GRP78 expression in metastatic MG63.3 cells via shRNA increases the median survival time in mice. A
schematic diagram (A) of the in vivo experimental metastasis survival study is shown. (B) Doxycycline-induced shGRP78_1 (gray line)
group exhibited a significantly longermedian survival time (47 days) compared with noninduced control group (dashed line, median survival:
33 days, log-rank test P b .0001) and nontargeting shRNA control group (solid black line: 37 days, log-rank test P b .001). (C)
Doxycycline-induced shGRP78_2 (gray line) group exhibited a significantly longer median survival time (43 days) compared with noninduced
control group (dashed line,median survival: 31 days, log-rank test P b .0001) and nontargeting shRNAcontrol group (solid black line: 37 days,
log-rank test P b .05). (D) Representative ex vivowhole-mount fluorescence imaging showing the burden of disease in lungs of mice without
doxycycline treatment orwith doxycycline treatment. Images from the shGRP78_1, shGRP78_2, and nontargeting shRNA control are shown.
A fluorescence image of a lung without tumor burden is shown for comparison.
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positive control, bone tissue served a negative control, and human
testes stained without primary antibodies against GRP78 served as an
omission control to assess background levels of staining. It is worth
noting that in nonmatched primary bone tumor cores, neoplastic cells
strongly stained positive for GRP78, indicating that the stress
responses required for lung metastasis are active in highly metastatic
cell populations of primary tumors (data not shown).
GRP78 Is Required for Lung Metastasis Progression in a
Murine Model of Breast Cancer Metastasis
To assess whether upregulation of GRP78 and its link to high
metastatic potential can be generalized to other types of cancers suchas breast cancer, we performed similar analyses on a commonly
studied, clonally related pair of murine breast cancer cell lines highly
metastatic 4T1 cells and poorly metastatic 67NR cells. By confocal
microscopy, 4T1 and 67NR cells had comparable levels of GRP78
when they arrived in the lung (day 0); however, at 14 days, 4T1 cells
were observed to have a significantly higher staining area for GRP78
compared with 67NR cells (Figure 5A). By Western blotting, an
enhanced upregulation of GRP78 in 4T1 cells versus 67NR cells was
observed when cells were exposed to increasing concentrations of
tunicamycin (Figure 5B). High-throughput immunofluorescence-based
quantification of GRP78 expression at the single cell level (Figure 5C)
demonstrates that highly metastatic 4T1 cells exhibited a significantly
higher fold change inGRP78 expression comparedwith poorlymetastatic
Figure 4. GRP78 is expressed in human OS metastatic lung tissue. (A) GRP78 is expressed in metastatic lung tissue biopsy cores from
human OS patient samples. Positive staining tissue (human testes), negative control (bone), and omission control (no primary antibodies,
human testes) are shown below. (B) Image quantification of the number of biopsy cores stained with OS cells staining positive for GRP78.
The percentage of OS cells staining positive for GRP78 is binned on the y-axis. The majority of the biopsy cores had OS cells staining
positive for GRP78.
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accomplished using IT-139 treatment (Figure 5D). Downmodulation of
GRP78 did not greatly affect cell proliferation in vitro in the absence of
any stress (Figure 5D); however, in the context of the lung
microenvironment (PuMA model), inhibition of GRP78 significantly
inhibited metastatic outgrowth (Figure 5D).
General Model of GRP78’s Role in Metastatic Cancer Cell
Adaptation to the Lung Microenvironment
A diagram of how GRP78 upregulation is necessary for lung
metastasis progression is shown in Figure 6. Highly metastatic cancer
cells are able to adapt to microenvironmental stressors by upregulating
the expression of ER-stress responsive genes such as GRP78, which
increases the protein-folding capacity of the ER. Increased ER
function permits the metastatic cancer cell to adapt and survive the
adverse conditions of the lung microenvironment; this in turn is
permissive for metastatic cell growth and results in a large tumor
burden in the lung. Antagonizing a metastatic cancer cell's ability to
adapt and survive in the lung by inhibiting GRP78 upregulation via
genetic knockdown or drug treatment results in increased cellular
stress and creates nonpermissive conditions for metastatic growth,
which would result in a lower tumor burden in the lung.
Discussion
The current report provides several lines of evidence supporting our
hypothesis that ER-stress adaptation (particularly GRP78 upregula-
tion) in highly metastatic cancer cells is causally linked to theirmetastatic potential. The significance of GRP78 during lung
metastasis progression was first realized from our transcriptomic
data where GRP78 was consistently upregulated in three different
highly metastatic human OS cell lines. GRP78 is often upregulated
when cells experience stressful conditions such as glucose deprivation,
low ATP levels, loss of ER Ca2+ stores, and redox imbalance [31]. We
wanted to determine whether the difference in GRP78 expression
between highly metastatic cancer cells and poorly metastatic cancer
cells can be recapitulated in vitro by challenging the cells with
pharmacological inducers of ER stress. Indeed, highly metastatic
cancer cells consistently exhibited a robust upregulation of
GRP78, whereas poorly metastatic cancer cells did not upregulate
GRP78 to the same extent. Altogether, these results suggest
that highly metastatic cells show a greater degree of adaptability in
stressful conditions, which may explain why highly metastatic cells are
more successful at colonizing the lung compared with poorly
metastatic cells.
Definitive evidence for the biological relevance of GRP78
expression during metastatic progression comes from our knockdown
studies where metastatic outgrowth in the lung was inhibited.
Although our drug and shRNA knockdown strategies managed to
partially knock down GRP78 in several highly metastatic cell lines, this
partial knockdownwas sufficient enough to inhibitmetastatic growth in
the PuMA model. These observations suggest that complete
knockdown of GRP78 levels may not be necessary to have
antimetastatic activity, and this information would be useful in the
Figure 5. Downmodulation of GRP78 in highly metastatic murine mammary adenocarcinoma 4T1 cells via pharmacologic inhibition
diminishes their metastatic potential in the lung. (A) Image analysis of GRP78 staining area per tumor cell in confocal images of tissue
sections of paraffin-embedded, formalin-fixed PuMA lung tissue. Tissue sections from PuMA lung slices with 4T1 or 67NR were stained
at day 0 and day 14 postinjection. Dashed white lines delineate where GFP-expressing murine breast cancer cells are located, and the
corresponding GRP78 expression in the cancer cells is shown below. Scale bar = 10 μm. Quantification of the mean area of GRP78
staining per tumor cell for 4T1 and 67NR cells is shown for day 0 and day 14 in the PuMA model; shown in the box and whisker plot
(5%-95% percentile) below the confocal images. Mann-Whitney U test, P b .0001. (B) Western blots demonstrating the in vitro enhanced
upregulation of GRP78 in 4T1 cells versus 67NR cells upon 24-hour treatment with tunicamycin (with concentrations indicated). (C)
High-throughput, image cytometry-based immunofluorescence quantification of GRP78 expression in 4T1 and 67NR cells treated with
tunicamycin (12.5 nM and 25 nM) for 24 hours. Representative micrographs of each condition are shown. Scale bar = 40 μm.
Quantification of the fold-change in the fluorescence due to GRP78 expression (normalized to vehicle) is shown in the adjacent bar
graphs; mean and standard error are shown. Kruskal-Wallis test, P b .0001; Dunn's multiple comparisons test, P b .05. (D) Pharmacologic
downmodulation of GRP78 via IT-139 treatment. Increasing doses of IT-139 resulted in a dose-dependent knockdown of GRP78. IT-139
treatment at 50 μM did not affect in vitro cell proliferation but inhibited metastatic outgrowth in the PuMA model, as shown by the
fluorescence micrographs. Scale bar = 1 mm. Quantification of lung tumor burden at day 14 is shown between vehicle- and IT-139–
treated PuMA lung slices; shown in the box and whisker plot (5%-95% percentile). Mann-Whitney U test, P b .01, n = 6.
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in vivo studies where GRP78 partial knockdown via shRNA in highly
metastatic cancer cells resulted in longer median survival times in mice.
GRP78 is a multifunctional protein that facilitates nascent protein
translocation into the ER, protein folding within the ER, and binding
to ER Ca2+. More importantly, GRP78 has a critical role in ER stressresponse because it functions to bind and inactivate three ER stress
“sensors” that initiate of ER-stress responses (IRE1, PERK, and
ATF6) [31–33]. The data from our studies suggest that the lung
causes upregulation of GRP78 in highly metastatic OS cells, although
the exact cause(s) of GRP78 upregulation remains unclear. The
requirement of GRP78 upregulation for metastatic cancer cell survival
Figure 6. A diagram that illustrates a proposed model of how GRP78 upregulation in highly metastatic cancer cells contributes to
metastatic progression in the lung. Upon arrival in the lung, highly metastatic cancer cells experience microenvironmental stressors
(higher O2 tension, redox imbalance, difference in nutrients supply) that can negatively protein folding and chaperone activity in the ER.
Highly metastatic cancer cells adapt to these stresses by increasing ER chaperone capacity by upregulating GRP78 expression. Increased
ER function allows the cancer cell to maintain cellular homeostasis which permits survival and growth in the lung. GRP78 upregulation is
linked to metastatic potential because downmodulation of GRP78 expression via shRNA or IT-139 drug treatment results in lower
metastatic outgrowth in the lung, thereby increasing median survival times in our in vivo experimental metastasis model.
Neoplasia Vol. 18, No. 11, 2016 Lizardo et al. 709and growth in the lung is consistently seen in human and murine cell
models and in both OS and breast cancer cells. Furthermore, we
demonstrated that the small molecule drug IT-139 has antimetastatic
activity in the ex vivo PuMA model. These data support the biological
relevance of the target, but further studies are needed to explore dose
and regimen before this pharmacological agent can be translated into
human adjuvant trials that target metastatic progression. It would be
worthwhile to assess whether other GRP78-targeting chemical com-
pounds such as HA15 [34] and medicarpin [35] have antimetastatic
effects. Bioconjugates such asMab159 [36] andBMTP78 [37] that target
GRP78 have been shown to have antimetastatic effects. It is important to
note that although our data may be relevant tomany cancers, the result in
pediatric OS addresses a critical and unmet need in the field.
To conclude, this report is the first to demonstrate a causal link
between upregulated GRP78 expression and metastatic potential. We
propose that GRP78 upregulation is an important adaptive response
used by highly metastatic cancer cells when they disseminate to the
lung and is a critical driver for lung metastatic progression. Therefore,
GRP78 is an attractive target deserving of additional translational
studies in the setting of inhibition of lung metastasis progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.09.001.
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